JPMorgan keeps Bayer stock target at EUR 61.00

Published on 10/02/2026 at 15:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

JPMorgan rates Bayer stock Overweight at a EUR 61.00 target. The quote is EUR 45.02 on October 2, 2026 versus EUR 45.33, below EUR 53.92.

Aquarellillustration der Skyline von Leverkusen mit Kühltürmen, Industrieschornsteinen und Hochhäusern am Rhein bei orangenem Abendhimmel, Beschriftung LEVERKUSEN — Aquarell-Panorama der Leverkusener Industrieskyline am Rhein bei Abendrot, Illustration mit AI erstellt.

Bayer (ISIN DE000BAY0017) was trading at EUR 45.02 at Lang & Schwarz on October 2, 2026 at 3:35 p.m. CEST, down 0.68 percent versus the prior close of EUR 45.33. 4investors reported on October 2, 2026 that JPMorgan retained its Overweight rating and EUR 61.00 price target, while warning that early expectations for the third quarter may be too high.

JPMorgan sees timing risk

The target is EUR 15.98 above the Lang & Schwarz price, equivalent to 35.45 percent using the price-target comparison. JPMorgan linked its caution to timing in Bayer's agricultural business rather than a fundamental change to its full-year expectations, according to 4investors on October 2, 2026.

The immediate counterweight is legal uncertainty. The same report said the Glyphosate dispute and US litigation continued to shape the market view, separating Bayer's operating progress from the legal overhang.

Q2 sales rose 2.00 percent

Bayer's Q2 2026 earnings call put sales at EUR 10.90 billion, up 2.00 percent from the prior-year quarter. First-half 2026 sales reached EUR 24.30 billion, an increase of 3.00 percent from the same period a year earlier, according to Yahoo Finance.

The earnings call also reported core earnings per share of EUR 3.66 for the first six months of 2026. Q2 core earnings per share were EUR 0.95, down 17.00 percent from the prior-year quarter, showing why the sales increase alone does not settle the investment case.

Stock remains below yearly high

Bayer's EUR 45.02 reference price stood 16.51 percent below the 52-week high of EUR 53.92 and above the 52-week low of EUR 25.78 on October 2, 2026. Market capitalization was EUR 44.30 billion at the finance quote timestamp of 3:29 p.m. CEST.

Next results arrive November 3

Bayer's investor calendar lists the Q3 2026 results and quarterly statement for November 3, 2026, alongside the investor video call and media update, according to Bayer. That date makes the agricultural timing debate and the earnings-per-share comparison the next measurable tests for the stock.

Legal risk meets operating progress

The market picture is therefore divided between a 35.45 percent target premium from JPMorgan and a 16.51 percent gap to Bayer's 52-week high. Bayer's next report will show whether the 2.00 percent Q2 sales growth can translate into stronger profitability while litigation remains a central valuation factor. The further course of trading is shown by the continuously updated real-time quote of Bayer stock.